Portal vein arterialization using an accessory right hepatic artery in liver transplantation

Siegfredo Paloyo, Seigo Nishida, Ji Fan, Akin Tekin, Gennaro Selvaggi, David Levi, Andreas Tzakis – 30 March 2013 – Portal vein thrombosis remains to be a challenging issue during liver transplantation even with the acquisition of innovative surgical techniques and years of experience. Most frequently, an initial eversion thromboendovenectomy is performed and depending on the extent of thrombosis and intraoperative findings, further revascularization options include venous jump grafts, portocaval hemitransposition, renoportal anastomosis or portal vein arterialization.

Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice

Jean‐Philippe Pradere, Johannes Kluwe, Samuele Minicis, Jing‐Jing Jiao, Geum‐Youn Gwak, Dianne H. Dapito, Myoung‐Kuk Jang, Nina D. Guenther, Ingmar Mederacke, Richard Friedman, Ana‐Cristina Dragomir, Costica Aloman, Robert F. Schwabe – 28 March 2013 – Although it is well established that hepatic macrophages play a crucial role in the development of liver fibrosis, the underlying mechanisms remain largely elusive. Moreover, it is not known whether other mononuclear phagocytes such as dendritic cells (DCs) contribute to hepatic stellate cell (HSC) activation and liver fibrosis.

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale‐up in the age of direct‐acting antivirals

Natasha K. Martin, Peter Vickerman, Jason Grebely, Margaret Hellard, Sharon J. Hutchinson, Viviane D. Lima, Graham R. Foster, John F. Dillon, David J. Goldberg, Gregory J. Dore, Matthew Hickman – 28 March 2013 – Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone.

Subscribe to